Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | F2R | P25116 | 6/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771748 | 0.87 | PTGES (0.69) | MAPTLMNASMN1; SMN2PPARGF2R | |
| SCHEMBL3771548 | 0.87 | BCHE (0.68) | MAPTLMNASMN1; SMN2F2RBCHE | |
| SCHEMBL3774731 | 0.87 | MAPT (0.54) | MAPTLMNASMN1; SMN2BCHEKMT2A | |
| SCHEMBL3774815 | 0.87 | TP53 (0.58) | MAPTLMNASMN1; SMN2PPARGF2R | |
| SCHEMBL3773611 | 0.84 | CA2 (0.53) | MAPTLMNASMN1; SMN2BCHEKMT2A | |
| SCHEMBL3772291 | 0.84 | MAPT (0.68) | MAPTPPARGKMT2AHPGD | |
| SCHEMBL3770493 | 0.84 | KCNK3 (0.60) | MAPTLMNASMN1; SMN2F2RBCHE | |
| SCHEMBL3774150 | 0.82 | MAPT (0.57) | MAPTLMNASMN1; SMN2PPARGBCHE | |
| SCHEMBL3779538 | 0.81 | PTGES (0.74) | MAPTLMNAF2RKMT2AMEN1 | |
| SCHEMBL6724672 | 0.81 | MAPT (0.64) | MAPTLMNASMN1; SMN2BCHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | MAPT 1426/4885LMNA 2648/4885SMN1; SMN2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.